Blafarm, I was not here to witness the FDA slow
Post# of 148177
I was not here to witness the FDA slow walking leronlimab in HIV, but the evidence strongly supports that belief.
The argument that I offer is that most in power and the majority of their constituents don’t care much avoid HIV unless affected directly. It is always easier to dismiss the suffering of others that feel, physically or emotionally distant.
As well, HIV , in the US at least, does not offer an immediate the threat to the economy. No shutdowns for HIV.
Covid threatens nearly everyone and is much harder to ignore, even for the 1%. I believe that changes the calculus and will yield a different result for Cytodyn with leronlimab.